Copyright
©The Author(s) 2023.
World J Gastroenterol. Sep 7, 2023; 29(33): 4962-4974
Published online Sep 7, 2023. doi: 10.3748/wjg.v29.i33.4962
Published online Sep 7, 2023. doi: 10.3748/wjg.v29.i33.4962
Table 2 Comparison of main clinical practice guidelines for the management of portal vein thrombosis in non-cirrhotic patients
EASL 2016[30] | AASLD 2020[38] | ACG 2020[52] | Baveno VII 2022[35] | |
Classification | Acute; Chronic | Recent: < 6 mo; Chronic: > 6 mo | Acute; Chronic | Recent: < 6 mo; Chronic: > 6 mo |
Treatment | Acute: AC; Chronic: Not specified | Recent PVT: AC; Chronic complete PVT or cavernous transformation: No benefit from AC | Acute PVT: AC; Chronic: thrombophilia, progression of thrombus into mesenteric veins, current or previous evidence of bowel ischemia | Recent PVT: At diagnosis; Chronic PVT: After prophylaxis for portal hypertensive bleeding in high-risk varices |
Choice of anticoagulation | LMWH, VKA | LMWH, VKA, DOACs | UFH, LMWH for initiation; LMWH or VKA for maintenance (DOACs absorption limited in the presence of intestinal oedema) | LMWH, VKA, DOACs |
Duration of treatment | At least 6 mo in presence of transient risk factor; long term for persistent risk factor or in case of chronic PVT with history of intestinal ischemia or recurrent thrombosis | AC for 3 mo | At least 6 mo for acute without thrombophilia; long term with thrombophilia | Recent PVT: At least 6 mo; Chronic: Long term for patient with permanent prothrombotic state |
Notes | EVL can be performed safely without withdrawing VKA |
- Citation: Monaco G, Bucherini L, Stefanini B, Piscaglia F, Foschi FG, Ielasi L. Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art. World J Gastroenterol 2023; 29(33): 4962-4974
- URL: https://www.wjgnet.com/1007-9327/full/v29/i33/4962.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i33.4962